Krishna Institute of Medical Sciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Krishna Institute of Medical Sciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 79% in 3 years, but profit fell: ₹6 less profit per ₹100 of extra sales. Lower than 89% of Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 15% of its market value (net debt). Lower than 87% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹172Over the last 3 years, every ₹100 of reported profit came with ₹172 of operating cash.
Higher than 79% of Healthcare companies in India.
Self-Funding Ratio
0.5×Over the last 3 years its own operating cash paid for 52% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 80% of Healthcare companies in India.
Cash Locked Ratio
₹3For every ₹100 of sales, ₹3 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹4 tied up three years earlier.
Less money tied up than 81% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
−₹6Sales grew 79% in 3 years, but profit fell: ₹6 less profit per ₹100 of extra sales.
Lower than 89% of Healthcare companies in India.
Asset Productivity Ratio
+79% / +164%In 3 years sales changed by +79% while total assets changed by +164%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.9×Debt due within a year is covered 0.9 times by its yearly operating cash.
Lower than 57% of Healthcare companies in India.
Cash Cushion Ratio
−15%Debt, after subtracting cash, equals 15% of its market value (net debt).
Lower than 87% of Healthcare companies in India.
Tangible Assets Ratio
95%Of every ₹100 the company owns, ₹95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 61% of Healthcare companies in India.
Tangible Net Worth Ratio
82%Of every ₹100 of net worth, ₹82 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 71% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Krishna Institute of Medical Sciences Limited owes ₹0.67 for every ₹1 it owns. Net profit fell 37% in the year to Mar 2026, and shrank 10% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
130.4Investors pay ₹130.4 for every ₹1 of Krishna Institute of Medical Sciences Limited's yearly profit, higher than 93% of Healthcare companies in India.
P/B ratio
12.43The share price is 12.43 times Krishna Institute of Medical Sciences Limited's book value per share, higher than 90% of Healthcare companies in India.
Market cap
₹27,937 CrThe total market value of all of Krishna Institute of Medical Sciences Limited's shares at today's price (share price × number of shares), larger than 81% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹2,247 CrWhat Krishna Institute of Medical Sciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹53.51Net worth divided by the number of shares. The share price of ₹665.15 is 12.4 times this, which is the P/B above.
Return on equity (ROE)
9.1%Krishna Institute of Medical Sciences Limited earned 9.1% on its shareholders' money over the last year, lower than 71% of Healthcare companies in India.
Owes vs Owns
0.67×Krishna Institute of Medical Sciences Limited owes ₹0.67 for every ₹1 it owns (moderate), higher than 96% of Healthcare companies in India.
Dividend yield
NoneKrishna Institute of Medical Sciences Limited does not currently pay a dividend.
Revenue growth
+29%Revenue rose 29% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Profit growth
-37%Net profit fell 37% in the year to Mar 2026, and shrank 10% a year on average over 3 years.
Profit margin
6.2%Krishna Institute of Medical Sciences Limited keeps ₹6 of every ₹100 of revenue as net profit.
Cash quality
2.1×Cash from Krishna Institute of Medical Sciences Limited's business was 2.1× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
2.7×Krishna Institute of Medical Sciences Limited's operating profit covered its interest costs 2.7 times in the year to Mar 2026.
Cash vs debt
Net debtKrishna Institute of Medical Sciences Limited had ₹4,182 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Krishna Institute of Medical Sciences Limited's P/E ratio?
Investors pay ₹130.4 for every ₹1 of Krishna Institute of Medical Sciences Limited's yearly profit, higher than 93% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Krishna Institute of Medical Sciences Limited: ₹27,937 Cr ÷ ₹2,247 Cr (31 Mar 2026) = 12.4.
What is Krishna Institute of Medical Sciences Limited's return on equity?
Krishna Institute of Medical Sciences Limited earned 9.1% on its shareholders' money over the last year, lower than 71% of Healthcare companies in India.
How much does Krishna Institute of Medical Sciences Limited owe compared with what it owns?
Krishna Institute of Medical Sciences Limited owes ₹0.67 for every ₹1 it owns (moderate), higher than 96% of Healthcare companies in India.
Does Krishna Institute of Medical Sciences Limited pay a dividend?
No. Krishna Institute of Medical Sciences Limited does not currently pay a dividend.
Is Krishna Institute of Medical Sciences Limited's revenue growing?
Revenue rose 29% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.